Form 4: Cingulate CEO Awarded Stock Options as Part of 2024 Bonus

Cingulate Inc.'s CEO, Shane J. Schaffer, received 27,638 stock options as part of his 2024 bonus.

Summary

• Shane J. Schaffer, the CEO of Cingulate Inc., was granted 27,638 stock options.
• These options were awarded as part of his 2024 bonus compensation.
• The options have an exercise price of $4.76 per share.
• The options vest immediately and expire on January 17, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. The immediate vesting is a positive for the executive.

Positives

• The granting of stock options aligns the CEO's interests with those of the shareholders.
• The immediate vesting of the options provides an incentive for the CEO to remain with the company.

Management Comments

• The option was granted for a portion of Mr. Schaffer's 2024 bonus.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of immediate exercisability is less common than a phased vesting schedule, but not unheard of.
• The exercise price of $4.76 is a key factor in determining the value of the options to the executive.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign of management's commitment to the company's success.
• The CEO benefits from the potential upside of the stock options.

Key Dates

Keywords

stock options, executive compensation, CEO, Cingulate Inc., bonus, equity